Gesamter Bestand

Auflistung Nach Schlagwort "enoxaparin"

Anzeige der Dokumente 1-12 von 12

    • Administration of low-molecular-weight heparin in patients with two or more unsuccessful IVF/ICSI cycles: a multicenter cohort study 

      Siristatidis C., Dafopoulos K., Salamalekis G., Galazios G., Christoforidis N., Moustakarias T., Koutlaki N., Bouschanetzis C., Loutradis D., Drakakis P. (2018)
      To compare the effects of the administration of low-molecular-weight heparin (LMWH) in subfertile patients with two or more unsuccessful IVF/ICSI cycles. In this six-center two-arm retrospective cohort study, the study ...

    • Cardiac autonomic function during intradialytic exercise training 

      Kaltsatou A., Hadjigeorgiou G.M., Grigoriou S.S., Karatzaferi C., Giannaki C.D., Lavdas E., Fotiou D., Kouidi E., Patramani G., Vogiatzi C., Pappas A., Stefanidis I., Sakkas G.K. (2019)
      Objectives: Cardiac autonomic nervous system (ANS) dysfunction is a common feature in patients receiving hemodialysis (HD) therapy, whilst is associated with an increased risk of ventricular arrhythmias and sudden cardiac ...

    • A case of membranous nephropathy associated with Sjögren syndrome, polymyositis and autoimmune hepatitis 

      Stefanidis, I.; Giannopoulou, M.; Liakopoulos, V.; Dovas, S.; Karasavvidou, F.; Zachou, K.; Koukoulis, G. K.; Dalekos, G. N. (2008)
      Sjögren syndrome (SS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, especially lacrimal and salivary. The immunologic process which occurs in this syndrome is B cell ...

    • Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece 

      Gourzoulidis G., Kourlaba G., Kakisis J., Matsagkas M., Giannakoulas G., Gourgoulianis K.I., Vassilakopoulos T., Maniadakis N. (2017)
      Background and Objective: Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a major healthcare concern that results in substantial morbidity and mortality with great economic ...

    • Dabigatran: The anticoagulant we have long expected? 

      Tagarakis, G. I.; Karangelis, D.; Daskalopoulos, M. E.; Tsilimingas, N. B. (2010)
      Many researchers have until now united their efforts in the endeavor to discover new anticoagulants, which would be simpler to use and safer to administer, so that patients would avoid both thromboembolic events as well ...

    • Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach 

      Charitou T., Kontou P.I., Tamposis I.A., Pavlopoulos G.A., Braliou G.G., Bagos P.G. (2022)
      Available drugs have been used as an urgent attempt through clinical trials to minimize severe cases of hospitalizations with Coronavirus disease (COVID-19), however, there are limited data on common pharmacogenomics ...

    • Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19 

      Dalekos G.N., Stefos A., Georgiadou S., Lygoura V., Michail A., Ntaios G., Samakidou A., Giannoulis G., Gabeta S., Vlychou M., Petinaki E., Leventogiannis K., Giamarellos-Bourboulis E.J., Gatselis N.K. (2021)
      Aims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to the development of severe respiratory failure. In hospitalized-patients, prompt interruption of the virus-driven inflammatory process ...

    • Long-term intradialytic hybrid exercise training on fatigue symptoms in patients receiving hemodialysis therapy 

      Grigoriou S.S., Krase A.A., Karatzaferi C., Giannaki C.D., Lavdas E., Mitrou G.I., Bloxham S., Stefanidis I., Sakkas G.K. (2021)
      Purpose: Hemodialysis (HD) patients suffer from generalized weakness, exercise intolerance and muscle atrophy, all leading to generalized fatigue and lack of energy. HD patients spend at least 50% of their time in a ...

    • New prophylaxis strategies to reduce the risk of thromboembolism in cancer 

      Papadopoulos V., Tsapakidis K., Markou A., Kokkalis A., Aidarinis C., Kotsakis A. (2021)
      Introduction: Patients with cancer are at risk of thrombotic events, mainly deep vein thrombosis and/or pulmonary embolism. The thrombosis risk is generally 4–6 times higher than in a healthy population and depends on ...

    • Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry 

      Giannis D., Allen S.L., Tsang J., Flint S., Pinhasov T., Williams S., Tan G., Thakur R., Leung C., Snyder M., Bhatia C., Garrett D., Cotte C., Isaacs S., Gugerty E., Davidson A., Marder G.S., Schnitzer A., Goldberg B., McGinn T., Davidson K.W., Barish M.A., Qiu M., Zhang M., Goldin M., Matsagkas M., Arnaoutoglou E., Spyropoulos A.C. (2021)
      Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in coronavirus disease 2019 (COVID-19) inpatients. Whether ...

    • Prevalence of Hemorrhagic Complications in Hospitalized Patients with Pulmonary Embolism 

      Pagkratis N., Matsagas M., Malli F., Gourgoulianis K.I., Kotsiou O.S. (2022)
      Background: The prevalence of anticoagulant therapy-associated hemorrhagic complications in hospitalized patients with pulmonary embolism (PE) has been scarcely investigated. Aim: To evaluate the prevalence of hemorrhages ...

    • Safety of Anticoagulation in Patients Treated with Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation 

      Giustozzi M., Acciarresi M., Agnelli G., Caso V., Bandini F., Tsivgoulis G., Yaghi S., Furie K.L., Tadi P., Becattini C., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., D'Amore C., Giulia Mosconi M., Anna Cimini L., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Marcheselli S., Pezzini A., Poli L., Padovani A., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Athanasakis G., Makaritsis K., Karagkiozi E., Vadikolias K., Liantinioti C., Theodorou A., Halvatsiotis P., Mumoli N., Galati F., Sacco S., Tiseo C., Corea F., Ageno W., Bellesini M., Silvestrelli G., Ciccone A., Lanari A., Scoditti U., Denti L., Mancuso M., Ferrari E., Ulivi L., Orlandi G., Giannini N., Tassinari T., Luisa De Lodovici M., Rueckert C., Baldi A., Toni D., Letteri F., Giuntini M., Maria Lotti E., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Maimone Baronello M., Csiba L., Szabó L., Chiti A., Giorli E., Del Sette M., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel P., Vanacker P., Barlinn K., Barlinn J., Deleu D., Gourbali V., Paciaroni M., Masotti L. (2020)
      Background and Purpose: The optimal timing for starting oral anticoagulant after an ischemic stroke related to atrial fibrillation remains a challenge, mainly in patients treated with systemic thrombolysis or mechanical ...